Real World Study News Today

Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to...

Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...

01.02.2024 - Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart Detailed results from two global Phase III ...

ROCKLAND, Mass.--(BUSINESS WIRE)--Jan 22, 2024--

Merck a leading science and technology company today announced new realworld data that continue to reinforce the JAVELIN Bladder regimen of firstline platinumbased chemotherapy followed by BAVENCIO avelumab maintenance as a standard of care for eligible patients with locally advanced or metastatic urothelial carcinoma UC who do not progress on firstline chemotherapy.

Galderma announced today positive topline results from the phase III READY3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines frown lines and lateral canthal lines crows feet either alone singlearea or simultaneously.

Catherine C. Coombs, MD, presents data investigating venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia.

In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...

SHANGHAI, Oct. 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing